Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) granted equity inducement awards in the form of restricted stock units (RSUs) to five new non-executive employees under its 2020 Inducement Incentive Plan, as a material inducement to employment and in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards cover varying RSU amounts and vest over three to four years, generally in three equal annual installments, subject to each recipient’s continued employment through the applicable vesting dates. According to Neuronetics, the grants were approved by the Compensation Committee and are subject to the plan’s terms.

Market Context

Insider activity was classified as Net Buying over 90 days, providing a platform counterpoint to thi...

Analysis

Insider activity was classified as Net Buying over 90 days, providing a platform counterpoint to this employee-award announcement. The active S-3 resale registration and high short positioning were additional sourced risk factors to monitor.

Key Figures

New employees: five new non-executive employees RSU award: 18,000 RSUs RSU award: 12,000 RSUs +5 more

8 metrics

New employees five new non-executive employees Inducement awards

RSU award 18,000 RSUs Phillip McDaniel

RSU award 12,000 RSUs Phillip McDaniel

RSU award 9,000 RSUs Nicolas Jackson

RSU award 22,500 RSUs Martin Webb

RSU award 15,000 RSUs Martin Webb

RSU award 2,400 RSUs William Peschel

RSU award 2,400 RSUs Alex Vargas

Historical Context

5 past events · Latest: Jul 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 28	Center opening	Positive	+3.3%	Greenbrook opened a national center for advanced interventional psychiatry in Maryland.
Jul 28	Earnings date notice	Neutral	+3.3%	The company scheduled its second-quarter 2026 results release and conference call.
Jul 20	CFO appointment	Positive	-6.9%	Neuronetics appointed Nir Naor CFO and announced additional management changes.
Jul 06	Investor panel	Neutral	+10.6%	Management participated in a panel discussion and held institutional investor meetings.
Jun 02	Sales appointment	Positive	-10.9%	Neuronetics appointed Robert Greene senior vice president of sales.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company announcements produced mixed reactions, with several positive or neutral events followed by divergent price moves.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), transcranial magnetic stimulation, treatment-resistant depression, +1 more

5 terms

restricted stock units financial

"Restricted stock units (“RSUs”) --- Table Start ---"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

transcranial magnetic stimulation medical

"provider of transcranial magnetic stimulation (TMS) treatment"

A noninvasive medical treatment that uses a changing magnetic field delivered through a coil placed near the head to stimulate specific areas of the brain, much like tapping a piano key to make a particular note play. Investors care because devices, clinical trial results, insurance coverage, and regulatory approvals determine commercial adoption and revenue potential for makers of the machines, clinics that offer the therapy, and related healthcare suppliers.

treatment-resistant depression medical

"indicated for the treatment of treatment-resistant depression (“TRD”)"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

rems-certified regulatory

"Greenbrook treatment centers also offer SPRAVATO®"

REMS-certified means a healthcare provider, pharmacy, or patient has completed the training, registration, and procedural requirements set by a regulator’s Risk Evaluation and Mitigation Strategy (REMS) to handle a specific medicine safely. It matters to investors because REMS certification controls who can prescribe, dispense, or receive the drug, affecting how widely the product can be sold, the speed of patient access, and regulatory compliance risks—like a special license that limits distribution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to five new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Restricted stock units (“RSUs”) 

Name	Number of Inducement Plan RSUs	Vesting Schedule
Phillip McDaniel	18,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Phillip McDaniel	12,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Nicolas Jackson	9,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Martin Webb	22,500	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Martin Webb	15,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
William Peschel	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Alex Vargas	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.

About Neuronetics
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (“MDD”) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹ 

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

References
¹ The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO^® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO^®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.

FAQ

What inducement RSU grants did Neuronetics (STIM) announce on July 31, 2026?

Neuronetics announced RSU inducement grants to five new non-executive employees under its 2020 Inducement Incentive Plan. According to Neuronetics, the awards were approved by the Compensation Committee as material inducements to employment and are subject to time-based vesting and continued service conditions.

How do the Neuronetics (STIM) inducement RSUs vest for the new employees?

The inducement RSUs vest in three equal installments over three or four years, depending on the grant. According to Neuronetics, each one-third tranche vests on specified annual anniversaries of the grant date, subject to the recipient’s continued employment through each applicable vesting date.

Which Neuronetics (STIM) employees received inducement RSUs and in what amounts?

According to Neuronetics, Phillip McDaniel received grants of 18,000 and 12,000 RSUs, Nicolas Jackson 9,000 RSUs, Martin Webb 22,500 and 15,000 RSUs, and William Peschel and Alex Vargas 2,400 RSUs each, all subject to the company’s 2020 Inducement Incentive Plan terms.

Why did Neuronetics (STIM) use Nasdaq Listing Rule 5635(c)(4) for these RSU grants?

Neuronetics used Nasdaq Listing Rule 5635(c)(4) to issue equity awards as material inducements to employment without prior shareholder approval. According to Neuronetics, the Compensation Committee approved these RSUs specifically under this rule and the company’s 2020 Inducement Incentive Plan framework.

Are the Neuronetics (STIM) inducement RSUs performance-based or time-based awards?

The disclosed inducement RSUs are time-based awards, vesting on set future anniversaries of the grant date. According to Neuronetics, vesting depends on each employee’s continued service with the company through the applicable vesting dates, with no additional performance conditions described.

What plan governs the July 31, 2026 Neuronetics (STIM) inducement RSU grants?

The inducement RSU grants are governed by Neuronetics’ 2020 Inducement Incentive Plan. According to Neuronetics, all awards are subject to this plan’s terms and conditions, as well as to time-based vesting schedules that require ongoing employment for shares to vest.